21Oct 2025
Belzutifan Shows Durable Tumor Response in Advanced Pheochromocytoma and Paraganglioma

Belzutifan Shows Durable Tumor Response in Advanced Pheochromocytoma and Paraganglioma

In a phase 2 international trial (LITESPARK-015), belzutifan demonstrated antitumor activity in 72 patients with advanced pheochromocytoma or paraganglioma. Objective response was 26% and disease control 85%, with median progression-free survival of 22.3 months. The treatment also reduced antihypertensive medication needs, with manageable safety.

  • #family health
  • #oncology

Like

Save

Share